RLMD — Relmada Therapeutics Balance Sheet
0.000.00%
Last trade - 00:00- $733.18m
- $640.18m
Annual balance sheet for Relmada Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 212 | 148 | 96.3 | 44.9 | 93 |
| Net Total Receivables | 0.086 | 0.512 | 0 | — | — |
| Prepaid Expenses | |||||
| Total Current Assets | 223 | 153 | 97.5 | 45.8 | 94 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 0 | — | — | — | — |
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 223 | 153 | 97.6 | 45.8 | 94 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Current Liabilities | 15.1 | 12.5 | 12.2 | 10.3 | 6.43 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 15.1 | 12.5 | 12.2 | 10.3 | 7.49 |
| Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | 208 | 140 | 85.4 | 35.5 | 86.5 |
| Total Liabilities & Shareholders' Equity | 223 | 153 | 97.6 | 45.8 | 94 |
| Total Common Shares Outstanding |